{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Samrat Pharmachem Ltd
Samrat Pharmachem Stock Falls to 52-Week Low of Rs.251 Amidst Prolonged Underperformance
Samrat Pharmachem’s shares touched a fresh 52-week low of Rs.251 today, marking a significant price level amid a year of sustained underperformance relative to the broader market and sector peers.
Why is Samrat Pharma falling/rising?
On 25-Nov, Samrat Pharmachem Ltd’s stock price fell by 1.54% to close at ₹265.00, continuing a sustained period of underperformance relative to both its sector and the broader market benchmarks.
Samrat Pharmachem Falls to 52-Week Low of Rs.265 Amidst Continued Downtrend
Samrat Pharmachem’s stock price reached a fresh 52-week low of Rs.265 today, marking a significant decline amid ongoing downward momentum. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year.
Samrat Pharmachem Stock Falls to 52-Week Low of Rs.266.1 Amidst Continued Downtrend
Samrat Pharmachem has reached a new 52-week low of Rs.266.1 today, marking a significant decline in its stock price amid a broader market rally. The pharmaceutical company’s shares have slipped below all major moving averages, reflecting persistent pressures on its valuation and performance over the past year.
Is Samrat Pharma overvalued or undervalued?
As of November 18, 2025, Samrat Pharma is considered overvalued with a PE Ratio of 53.48, significantly higher than its peers, and has experienced a poor year-to-date return of -29.33%, indicating a shift in market perception from very attractive to very expensive.
Is Samrat Pharma overvalued or undervalued?
As of November 17, 2025, Samrat Pharma's valuation has improved to very attractive, indicating it is undervalued with a PE ratio of 53.08 and favorable metrics compared to competitors, despite a recent year-to-date return of -29.85% against the Sensex, while maintaining a strong long-term outlook with a 5-year return of 138.54%.
How has been the historical performance of Samrat Pharma?
Samrat Pharma's historical performance shows fluctuating financial metrics, with net sales rising from INR 137.45 crore in March 2020 to a peak of INR 310.65 crore in March 2023, followed by a decline and slight recovery. Key indicators like operating profit and profit after tax also experienced significant volatility during this period.
Samrat Pharmachem Stock Plummets to 52-Week Low of Rs. 266.55
Samrat Pharmachem has reached a new 52-week low, reflecting ongoing challenges in the market. The company's stock has declined significantly over the past year, underperforming compared to the broader market. Despite a historical growth in operating profits, recent financial results indicate a notable decrease in profitability.
How has been the historical performance of Samrat Pharma?
Samrat Pharma's historical performance indicates fluctuating profitability despite growth in net sales and total assets, with net sales rising from INR 137.45 crore in March 2020 to INR 285.86 crore in March 2025, but profit metrics declining significantly in recent years. Operating cash flow turned negative in March 2025, contrasting with previous positive trends.
Samrat Pharmachem Hits New 52-Week Low at Rs. 270.3
Samrat Pharmachem has reached a 52-week low, reflecting a significant decline in its stock price over the past year. The company has underperformed its sector and is trading below key moving averages. However, it maintains a positive return on capital employed and has seen increased foreign institutional investment.
Samrat Pharmachem Hits New 52-Week Low at Rs. 270.45
Samrat Pharmachem has reached a 52-week low, continuing a downward trend over the past four days. The stock is trading below all key moving averages and has declined significantly over the past year. Financial metrics indicate weak long-term performance, with recent quarterly results showing a notable decrease in profits.
Why is Samrat Pharma falling/rising?
As of 06-Nov, Samrat Pharmachem Ltd's stock price is at 280.00, down 1.93% and has fallen for three consecutive days, totaling a 3.73% decline. The stock is underperforming significantly against benchmarks, trading below key moving averages, and is close to its 52-week low, with no immediate catalysts for recovery.
Why is Samrat Pharma falling/rising?
As of 29-Oct, Samrat Pharmachem Ltd's stock price is at 299.95, showing a short-term rebound after recent declines but has significantly underperformed over the longer term with a year-to-date drop of 21.49%. Despite today's gains and increased investor participation, concerns about sustainability remain due to its historical performance.
Samrat Pharmachem Hits New 52-Week Low at Rs. 271.1
Samrat Pharmachem has hit a new 52-week low, reflecting a significant decline in its stock performance. The company has underperformed against benchmarks, with a notable drop in its PAT. Despite some volatility, it has struggled over the past year, contrasting sharply with broader market gains.
Why is Samrat Pharma falling/rising?
As of 28-Oct, Samrat Pharmachem Ltd's stock price is at 275.60, down 3.23% and recently hitting a 52-week low. The stock has significantly underperformed its sector and the broader market, with notable declines over various time frames.
Samrat Pharmachem Hits New 52-Week Low at Rs. 281 Amid Ongoing Decline
Samrat Pharmachem has reached a new 52-week low, continuing its downward trend with a notable decline over the past year. The company's financial performance shows significant decreases in key metrics, while foreign institutional investors have slightly increased their holdings, indicating mixed investor sentiment amidst ongoing challenges.
Samrat Pharmachem Hits New 52-Week Low at Rs. 281.1 Amid Market Struggles
Samrat Pharmachem has reached a 52-week low, reflecting a significant decline in its stock performance. The company is trading below all major moving averages and has experienced a substantial year-over-year drop. Despite weak financial metrics, foreign institutional investors have increased their holdings this quarter.
Samrat Pharmachem Hits New 52-Week Low at Rs. 285.1
Samrat Pharmachem has reached a new 52-week low, reflecting ongoing challenges in the Pharmaceuticals & Biotechnology sector. The stock has consistently underperformed key moving averages and has seen a significant decline over the past year. Recent quarterly results show a decrease in profit, while foreign institutional investors have increased their holdings.
Why is Samrat Pharma falling/rising?
As of 13-Oct, Samrat Pharmachem Ltd's stock price is Rs 297.25, down 2.28%, and has significantly underperformed with a year-to-date decline of 22.20%. Despite a recent increase in delivery volume, the stock remains close to its 52-week low and continues to trade below its moving averages, indicating a bearish trend amidst a stable broader market.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
